Ipca Laboratories Limited has announced the commencement of commercial production at its new greenfield Drug Intermediates and Active Pharmaceutical Ingredients (APIs) manufacturing facility. The company informed the stock exchanges about this significant milestone on February 9, 2026.

Facility Details and Investment

The new manufacturing facility is strategically located at Village Hingani in District Wardha, Maharashtra. The company has invested approximately Rs 182 crores in establishing this greenfield facility, which represents a substantial expansion of its manufacturing capabilities.

Regulatory Compliance and Communication

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was filed through online filing system and addressed to both major stock exchanges where the company's shares are listed.

The disclosure was signed by Harish P. Kamath, Corporate Counsel & Company Secretary (ACS 6792), on behalf of Ipca Laboratories Limited. The digital signature was authenticated on February 9, 2026, at 17:02:15 +05'30'.

Strategic Significance

This new facility enhances Ipca Laboratories' manufacturing footprint in the pharmaceutical sector, specifically focusing on Drug Intermediates and Active Pharmaceutical Ingredients production. The commencement of commercial production marks the successful completion of the facility setup and validation processes, enabling the company to begin revenue generation from this investment.

Ipca laboratories has announced that its Board of Directors will meet on February 13, 2026, to consider the company's unaudited financial results for the third quarter and nine months ended December 31, 2025. The pharmaceutical company formally notified both BSE and NSE exchanges about this scheduled board meeting on January 22, 2026, in compliance with regulatory requirements.

Board Meeting Details

The board meeting has been convened pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The directors will consider and take on record both standalone and consolidated unaudited financial results for the specified period.

Trading Window Restrictions

In accordance with insider trading regulations, Ipca Laboratories has implemented a trading window closure for company insiders. The restriction period was communicated to exchanges through a prior notification dated December 22, 2025.

The trading window closure details are as follows:

• Effective From: January 1, 2026
• Applicable To: Insiders as defined under SEBI (Prohibition of Insider Trading) Regulations, 2015
• Closure Period: Until 48 hours after financial results declaration
• Expected Reopening: February 15, 2026

Regulatory Compliance

The announcement demonstrates the company's adherence to regulatory frameworks governing listed entities in India. The formal communication was signed by Harish P. Kamath, Corporate Counsel & Company Secretary, ensuring proper authorization and compliance with disclosure requirements.

The scheduled board meeting represents a routine corporate governance activity, with the company maintaining transparency through timely regulatory disclosures. Investors and stakeholders can expect the Q3FY26 financial results to be announced following the board's consideration and approval on the scheduled date.